FB 301Alternative Names: FB-301
Latest Information Update: 12 Nov 2012
At a glance
- Originator Academia Sinica
- Developer Cytovance Biologics; Fountain BioPharma
- Class Antiallergics; Monoclonal antibodies
- Mechanism of Action IgE receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Hypersensitivity
Most Recent Events
- 31 Oct 2012 Clinical trials in Hypersensitivity in USA (Parenteral)
- 06 Apr 2011 Investigation in Hypersensitivity in Taiwan (Parenteral)